15018-50-5

Upstream product

• 15837-45-3 6-amino-1-phenyluracil 
• 77-78-1 dimethyl sulfate 
• 64-10-8 phenyl carbamate 
• 108-59-8 malonic acid dimethyl ester 
• 62-53-3 aniline 
• 105-53-3 diethyl malonate 
• 141-82-2 malonic acid 

Downstream Products

• 94212-33-6 5-((Ξ)-trans-cinnamylidene)-1-phenyl-barbituric acid 
• 91974-06-0 5-acetyl-1-phenyl-pyrimidine-2,4,6-trione 
• 68160-64-5 5-benzylidene-1-phenyl-pyrimidine-2,4,6-trione 
• 70450-58-7 5-anilinomethylene-1-phenyl-pyrimidine-2,4,6-trione 
• 61753-92-2 5-amino-1-phenyl-barbituric acid 
• 90767-12-7 1-phenyl-5-Bromobarbituric acid 
• 82628-28-2 1-phenylvioluric acid 
• 90948-22-4 5,5-dibromo-1-phenylbarbituric acid 
• 102-03-4 1-acetyl-3-phenylurea 
• 113861-01-1 5-(2-β-D-glucopyranosyloxy-benzylidene)-1-phenyl-barbituric acid 
• 103800-37-9 1-phenyl-5-(2-phenyl-chromen-4-ylidene)-pyrimidine-2,4,6-trione 
• 128226-08-4 7'-amino-1,1',2,2',3',4'-hexahydro-2,2',4'-trioxo-1'-phenylspiro<3H-indole-3,5'-<5H>pyrano<2,3-d>pyrimidine>-6'-carbonitrile 
• 128226-15-3 C₂₂H₁₅N₅O₄ 
• 128226-10-8 C₂₁H₁₂FN₅O₄ 

Relevant academic research and scientific papers

Selective cell adhesion inhibitors: Barbituric acid based α4β7-MAdCAM inhibitors

A novel series of barbituric acid derivatives were identified as selective inhibitors of α4β7 MAdCAM (mucosal addressin cell adhesion molecule-1) interactions via a high throughput screening exercise. These inhibitors were optimized to submicromolar potencies in whole cell adhesion assays, retaining their selectivity over α4β1 VCAM.

Synthesis of N-aryl and N-arylcarbamoylamino derivatives of 1,3-diazinane-5-carboxamide and their activity against glioblastoma LN-229 cell line

Six structural motifs based on the initial (lead) structure of merbarone were designed, prepared, and tested against the glioblastoma LN-229 cell line. Three different structural moieties were modified in the search for optimal glioblastoma activity: the 1,3-diazinane moiety, the aryl moiety, and the heteroatom linker. Calculated molecular descriptors such as lipophilicity (C log P), acidic strength (calculated pKa), and polar surface area (PSA) were used to design a diverse structural library of these compounds. From six different structural motifs and 136 compounds, a handful of examples with moderate (100 μg/ml), good (10 μg/ml) and excellent (1 μg/ml) glioblastoma activity were elucidated.

Pyrimidones including six hydrogens quinoline compound and its preparation method and application

The invention relates to a quinolines compound containing hexahydropyrimidone, which is represented by a formula I, as well as pharmaceutically acceptable configurational isomers, salts, hydrates, solvates and prodrugs thereof. According to the quinolines compound, substituent groups R1, R2, R3, X, Y, Z and n have definitions given in the specification. The invention further relates to the compound of the formula I and the configurational isomers which have a very strong effect of inhibiting c-Met kinase, further relates to an application of the compounds and the pharmaceutically acceptable salts, hydrates, solvates or prodrugs in preparing a medicine for treating diseases caused by hydrates high expression of the c-Met kinase, and particularly relates to an application of a medicine for preparing a medicine for treating and/or preventing cancers.

Synthesis and antifungal activity of substituted 2,4,6-pyrimidinetrione carbaldehyde hydrazones

Opportunistic fungal infections caused by the Candida spp. are the most common human fungal infections, often resulting in severe systemic infections - a significant cause of morbidity and mortality in at-risk populations. Azole antifungals remain the mainstay of antifungal treatment for candidiasis, however development of clinical resistance to azoles by Candida spp. limits the drugs' efficacy and highlights the need for discovery of novel therapeutics. Recently, it has been reported that simple hydrazone derivatives have the capability to potentiate antifungal activities in vitro. Similarly, pyrimidinetrione analogs have long been explored by medicinal chemists as potential therapeutics, with more recent focus being on the potential for pyrimidinetrione antimicrobial activity. In this work, we present the synthesis of a class of novel hydrazone-pyrimidinetrione analogs using novel synthetic procedures. In addition, structure-activity relationship studies focusing on fungal growth inhibition were also performed against two clinically significant fungal pathogens. A number of derivatives, including phenylhydrazones of 5-acylpyrimidinetrione exhibited potent growth inhibition at or below 10 μM with minimal mammalian cell toxicity. In addition, in vitro studies aimed at defining the mechanism of action of the most active analogs provide preliminary evidence that these compound decrease energy production and fungal cell respiration, making this class of analogs promising novel therapies, as they target pathways not targeted by currently available antifungals.

Discovery of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 5-(aminomethylene)pyrimidine-2,4,6-trione moiety as c-Met kinase inhibitors

A series of novel quinoline derivatives bearing 5-(aminomethylene) pyrimidine-2,4,6-trione moiety were designed, synthesized, and evaluated for their c-Met kinase inhibitory activities and antiproliferative activities against 5 cancer cell lines (HT-29, H460, MKN-45, A549, and U87MG) in vitro. Most compounds showed moderate to excellent potency, with the most promising analogue 45 (c-Met half-maximal inhibitory concentration [IC50] = 1.15 nM) showing high selectivity versus 5 other tyrosine kinases, VEGFR-2, Flt-3, PDGFR-β, c-Kit, and EGFR. Structure-activity relationship studies indicated that electron-donating groups on the phenyl ring at the 3-position of pyrimidine-2,4,6-trione were required to increase the electron density on the 5-(aminomethylene)pyrimidine-2,4,6-trione moiety.

Synthesis and antitumor evaluation of novel cyclic arylsulfonylureas: ADME-T and pharmacophore prediction

Novel derivatives of 5-(substituted)benzylidene-3-(4-substituted)phenylsulfonylimidazolidine-2,4-diones (3a-r), 1-(4-substituted)phenylsulfonyl-3-(4-substituted)phenylpyrimidine-2,4,6-(1H,3H,5H)-triones (6a-l), and 3-(4-substituted)phenyl-1-(4-substituted)phenylsulfonylquinazoline-2,4(1H,3H)- diones (8a-l) have been synthesized and tested for their antitumor activity against 60 tumor cell lines taken from 9 different organs. The tested compounds have showed good inhibitory effect at the ovarian cancer (IGROV1) cell line. A significant inhibition for (RXF393) renal cancer cells was observed with series 3 compounds, while in the other two series 6 and 8, there was a significant inhibition of ovarian cancer cells (OVCAR-8) and melanoma cells (SK-MEL-2). Interestingly; beside the strong inhibition of compound 3q to IGROV1 and RXF393 cells, a great inhibition (199.62%) for (M14) Melanoma cells was observed at the tested concentration (10?μM). ADME-T and pharmacophore prediction methodology were used to study the antitumor activity of the most active compounds and to identify the structural features required for antitumor activity.

Synthesis, biological active molecular design, and molecular docking study of novel deazaflavin-cholestane hybrid compounds

Novel deazaflavin-cholestane hybrid compounds, 3′,8′-disubstituted-5′-deazacholest-2,4-dieno[2,3-g]pteridine-2′,4′(3′H,8′H)-diones, have been synthesized by condensation reaction between 6-(monosubstituted amino)-pyrimidin-2,4(1H,3H)-diones and 2-hydroxymethylenecholest-4-en-3-one in presence of p-toluenesulfonic acid monohydrate and diphenyl ether. The antitumor activities against human tumor cell lines (CCRF-HSB-2 and KB cells) have been investigated in vitro, and many of these compounds showed promising antitumor activities. Furthermore, molecular docking study using LigandFit within the software package Discovery Studio 1.7 was done for lead optimization of these compounds as potential PTK inhibitors. In general, all of the synthesized steroid-hybrid compounds showed good binding affinities into PTK (PDB code: 1t46).

Synthesis of novel galactopyranosyl-derived spiro barbiturates

Malonic acid undergoes condensation readily with ureas to yield barbituric acids 2, which on bromination give 5,5-dibromobarbituric acids 3. Reaction of α-D-galactose with these 5,5-dibromo barbituric acids afforded 2,3-α-D-galactopyrano-1,4-dioxo-7,9-diaza-spiro[4,5]deca-6,8,10-triones 4. The structures of the products have been assigned on the basis of 1H NMR, 13C NMR, FAB-MS, optical activity, and elemental analysis. The title compounds are found to have antibacterial and antifungal activities.

A facile synthesis of 5-acylbarbituric acids under microwave irradiations

N-Monosubstituted and N,N'-disubstituted barbituric acids on treatment with benzoic anhydride/acetic anhydride under microwave irradiations without using any solvent provide a convenient methodology for the synthesis of 5-benzoyl/ acylbarbituric acids in moderate to high yields.

Chemical modification of plant alkaloids. 2. Reaction of cotarnine with barbituric acid derivatives and structure of 5-dihydrocotarnylbarbituric acids

The reaction of barbituric acid and its N-substituted derivatives and 2-thio analogs with cotarnine forms 5-(4-methoxy-6-methyl-5,6,7,8-tetrahydro-2H-1,3-methylenedioxy-[4,5-g]isoquinolinyl-1)barbituric acids, a new class of zwitter-ions, the structure of which was studied by 1H and 13C NMR spectroscopy and mass spectrometry. The prepared compounds exist in solution as stable intermolecular associates and have a complicated H-bonded structure.